Last updated: February 24, 2026
What is NDC 51660-0204?
NDC 51660-0204 refers to Methylphenidate Hydrochloride Extended-Release Tablets (brand name Concerta). Approved by the FDA, it is prescribed for Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy.
The drug is marketed by Janssen Pharmaceuticals and has been on the market since 2000.
Market Size and Demand Drivers
Global ADHD Treatment Market Overview
The global ADHD treatment market was valued at approximately USD 12 billion in 2021[1]. It is projected to grow at a CAGR of around 5% through 2028, driven by increased diagnosis rates, expanding drug indications, and new formulation development.
Key Market Segments
- North America: Largest market; accounting for around 60% of sales due to high diagnosis rates and established healthcare infrastructure.
- Europe: Growing demand; expected CAGR of 4% from 2022 to 2028.
- Asia-Pacific: Emerging market; driven by increasing awareness and diagnosis, projected CAGR of 6%.
Competitors and Market Share
Major competitors include:
- Concerta (Janssen)
- Adderall XR (Shire, now part of AbbVie)
- Vyvanse (Eli Lilly)
- Focalin XR (Novartis)
Concerta holds approximately 20-25% of the ADHD pharmacotherapy market share in the US[2].
Prescriptions and Revenue Data
- U.S. prescriptions: approximately 12 million annually (pre-pandemic 2019 data).
- Revenue for Concerta (Janssen): USD 2.5 billion in 2021[3].
Pricing Trends and Projections
Current Pricing
- Average wholesale price (AWP) for a 30-count, 36 mg tablet of Concerta is around USD 650.
- Average retail price: USD 12-15 per tablet.
- Monthly cost (30 days): USD 360-450 per patient.
Price Components
- Raw material costs are stable but can fluctuate based on global supply chain factors.
- Generic versions (e.g., Methylphenidate ER) entered the market in 2015, reducing prices by approximately 25-35%.
Projected Price Trends (Next 3-5 Years)
- Brand-name drug prices are expected to remain relatively stable due to patent protections until 2028.
- Generic versions will intensify price competition.
- Average wholesale price for branded Concerta is forecasted to decline by 10-15% over this period, primarily driven by generic market penetration.
- Market share shifts toward generics could lead to prices falling below USD 8 per tablet across retail channels.
Impact of Patent Expiry
Patents protecting Concerta extend until 2028[4], after which generics could reduce prices significantly, possibly leading to a 40-50% decrease in retail prices depending on market dynamics.
Regulatory and Market Risks
- Regulatory shifts: Potential for stricter healthcare policies or changes in prescription guidelines may impact demand.
- Market entry of biosimilars: While less common for small molecules, biosimilar activity could influence market prices.
- Supply chain disruptions: Could cause short-term volatility in prices and availability.
Summary of Price Outlooks
| Period |
Price Trend |
Expected Price Range (USD) per tablet |
Comment |
| 2023-2025 |
Slight decline |
USD 10-12 |
Due to generic competition and market saturation. |
| 2026-2028 |
Moderate decline |
USD 8-10 |
Patent expiration approaching; increased generic share. |
| Post-2028 |
Significant decline |
USD 4-6 |
Patent loss; wide availability of generics. |
Key Takeaways
- The ADHD market is expanding along with increasing diagnosis rates.
- Concerta remains a leading brand with substantial market share in the US.
- Prices are forecasted to decline over the next 3-5 years, especially post-patent expiry in 2028.
- Generic entry is the primary driver of downward price pressure.
- Market risks include regulatory changes and supply chain stability.
FAQs
-
What factors influence Concerta's pricing?
Manufacturing costs, patent status, generic competition, insurance coverage, and healthcare policies.
-
How will patent expiration impact prices?
Prices are expected to decrease substantially once patent protections lapse, due to increased competition from generics.
-
Are there upcoming formulations that could alter market dynamics?
Extended-release formulations such as Jornay PM and other long-acting alternatives are capturing market share.
-
What regions show the most growth potential for methylphenidate products?
Asia-Pacific and Latin America, driven by rising diagnosis rates and healthcare infrastructure improvements.
-
How do pricing strategies differ between brand and generic methylphenidate products?
Brand-name drugs maintain premium pricing; generics compete on price, often resulting in significant discounts within 2-3 years of patent expiry.
References
[1] Grand View Research. (2022). ADHD Treatment Market Size, Share & Trends Analysis.
[2] IQVIA. (2021). US Prescription Data for ADHD Medications.
[3] Janssen. (2022). Annual Financial Report.
[4] U.S. Patent and Trademark Office. (2022). Patent Expiry Data for Concerta.
